CompareMarketResearchRequest a sample
Home / Healthcare / Injectable Drug Delivery

Healthcare · Market report

Injectable Drug Delivery Market Size, Share and Forecast 2026-2036

The global injectable drug delivery market is worth USD 19.6 bn in 2026 and is forecast to reach USD 46.4 bn by 2036, growing at a 9.0% CAGR. United States is the largest country market and Prefilled syringes is the largest by device segment.

USD 19.6 bnMarket size 2026
USD 46.4 bnForecast 2036
9.0%CAGR 2026-2036
United StatesLargest country

Request a free sample Jump to the forecast

Report price: Starts from USD 1,999

5 segmentation views25 countries2026 to 2036 yearly forecast

Market overview

The global injectable drug delivery market is worth USD 19.6 bn in 2026 and is forecast to reach USD 46.4 bn by 2036, growing at a 9.0% CAGR. United States is the largest country market and Prefilled syringes is the largest by device segment.

ScopeInjectable drug delivery devices: prefilled syringes, autoinjectors, pen injectors, cartridges, needle-free injectors and on-body injectors sold to drug makers and patients.
IndustryHealthcare
Value 2025USD 18.0 bn
Value 2026USD 19.6 bn
Value 2036USD 46.4 bn
CAGR 2026-20369.0%
Volume 202615,184 million units
Volume 203634,197 million units
Average price 2026USD 1.29 per unit
Report priceStarts from USD 1,999
PublishedNovember 2026

Request a free sample of this report

Injectable Drug Delivery market size and forecast, 2026-2036

Exhibit 1The global injectable drug delivery market is forecast to grow from USD 19.6 bn in 2026 to USD 46.4 bn by 2036, more than doublingGlobal market value in USD: 2025 base year, 2026 estimate and forecast to 2036. CAGR 2026 to 2036: 9.0%
Injectable Drug Delivery market value, 2025 to 2036Market value by year. 2025: USD 18.0 bn; 2026: USD 19.6 bn; 2027: USD 21.4 bn; 2028: USD 23.3 bn; 2029: USD 25.4 bn; 2030: USD 27.7 bn; 2031: USD 30.2 bn; 2032: USD 32.9 bn; 2033: USD 35.9 bn; 2034: USD 39.1 bn; 2035: USD 42.6 bn; 2036: USD 46.4 bn. Compound annual growth rate 2026 to 2036: 9.0%.202519.6 bn202630.2 bn203146.4 bn20369.0% CAGR

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

YearMarket value
2026USD 19.6 bn
2027USD 21.4 bn
2028USD 23.3 bn
2029USD 25.4 bn
2030USD 27.7 bn
2031USD 30.2 bn
2032USD 32.9 bn
2033USD 35.9 bn
2034USD 39.1 bn
2035USD 42.6 bn
2036USD 46.4 bn

Injectable Drug Delivery market segmentation

By device

Exhibit 2Prefilled syringes is the largest segment by device, with 38.0% of 2026 revenueEstimated share of 2026 global revenue, by device
Injectable Drug Delivery market share by device, 2026Share of 2026 revenue by device. Prefilled syringes: 38.0%; Pen injectors and cartridges: 24.0%; Autoinjectors: 22.0%; On-body and wearable injectors: 10.0%; Needle-free injectors: 6.0%.Prefilled syringes38.0%Pen injectors and cartridges24.0%Autoinjectors22.0%On-body and wearable injectors10.0%Needle-free injectors6.0%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Prefilled syringes38.0%32.2%USD 7.5 bn7.2%
Pen injectors and cartridges24.0%21.3%USD 4.7 bn7.7%
Autoinjectors22.0%24.5%USD 4.3 bn10.2%
Needle-free injectors6.0%6.1%USD 1.2 bn9.2%
On-body and wearable injectors10.0%15.9%USD 2.0 bn14.2%

By therapy

Exhibit 3Diabetes and obesity adds the most revenue by therapy, growing from USD 7.1 bn in 2026 to USD 19.1 bn by 2036Estimated revenue in USD by therapy, 2026 and 2036 forecast
Injectable Drug Delivery market by therapy, 2026 and 2036Revenue by therapy in 2026 and 2036. Diabetes and obesity: USD 7.1 bn in 2026, USD 19.1 bn in 2036, change +171%; Autoimmune and inflammation: USD 3.9 bn in 2026, USD 9.3 bn in 2036, change +136%; Oncology: USD 2.7 bn in 2026, USD 6.5 bn in 2036, change +136%; Other: USD 2.7 bn in 2026, USD 6.2 bn in 2036, change +126%; Vaccines: USD 3.1 bn in 2026, USD 5.4 bn in 2036, change +70%.20262036 forecastChangeDiabetes and obesity+171%7.1 bn19.1 bnAutoimmune and inflammation+136%3.9 bn9.3 bnOncology+136%2.7 bn6.5 bnOther+126%2.7 bn6.2 bnVaccines+70%3.1 bn5.4 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Diabetes and obesity36.0%41.2%USD 7.1 bn10.5%
Autoimmune and inflammation20.0%20.0%USD 3.9 bn9.0%
Oncology14.0%14.0%USD 2.7 bn9.0%
Vaccines16.0%11.5%USD 3.1 bn5.5%
Other14.0%13.3%USD 2.7 bn8.5%

By end user

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Hospitals38.0%32.0%USD 7.5 bn7.1%
Clinics22.0%20.0%USD 4.3 bn8.0%
Home care40.0%48.0%USD 7.8 bn11.0%

By container material

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Glass52.0%42.0%USD 10.2 bn6.7%
Polymer36.0%42.0%USD 7.1 bn10.7%
Coated hybrid12.0%16.0%USD 2.4 bn12.2%

By administration route

SegmentShare 2026Share 2036Value 2026CAGR 2026-36
Subcutaneous44.0%48.0%USD 8.6 bn9.9%
Intramuscular24.0%22.0%USD 4.7 bn8.1%
Intravenous28.0%26.0%USD 5.5 bn8.2%
Intradermal and other4.0%4.0%USD 785 mn9.0%

Top 25 countries for injectable drug delivery by revenue

Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 84.5% of 2026 revenue and the 25 countries below together hold 96.0%.

Exhibit 4United States is the largest country market at USD 8.2 bn in 2026, and the three largest countries hold 58.0% of global revenueEstimated 2026 revenue in USD and share of the global market, ten largest countries
Injectable Drug Delivery market, ten largest countries in 2026Ten largest countries by 2026 revenue. United States: USD 8.2 bn, 42.0%; Germany: USD 1.6 bn, 8.0%; China: USD 1.6 bn, 8.0%; Japan: USD 1.2 bn, 6.0%; France: USD 883 mn, 4.5%; United Kingdom: USD 883 mn, 4.5%; Italy: USD 589 mn, 3.0%; India: USD 589 mn, 3.0%; Canada: USD 589 mn, 3.0%; Spain: USD 490 mn, 2.5%.United States8.2 bn 42.0%Germany1.6 bn 8.0%China1.6 bn 8.0%Japan1.2 bn 6.0%France883 mn 4.5%United Kingdom883 mn 4.5%Italy589 mn 3.0%India589 mn 3.0%Canada589 mn 3.0%Spain490 mn 2.5%

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

#CountryValue 2026Share 2026Value 2036CAGR 2026-36
1United StatesUSD 8.2 bn42.0%USD 19.9 bn9.2%
2GermanyUSD 1.6 bn8.0%USD 3.3 bn7.7%
3ChinaUSD 1.6 bn8.0%USD 4.7 bn11.7%
4JapanUSD 1.2 bn6.0%USD 2.3 bn6.8%
5FranceUSD 883 mn4.5%USD 1.9 bn7.7%
6United KingdomUSD 883 mn4.5%USD 1.9 bn7.7%
7ItalyUSD 589 mn3.0%USD 1.3 bn7.9%
8IndiaUSD 589 mn3.0%USD 1.8 bn11.6%
9CanadaUSD 589 mn3.0%USD 1.3 bn8.6%
10SpainUSD 490 mn2.5%USD 1.0 bn7.6%
11BrazilUSD 222 mn1.1%USD 604 mn10.5%
12South KoreaUSD 222 mn1.1%USD 483 mn8.1%
13AustraliaUSD 222 mn1.1%USD 483 mn8.1%
14SwitzerlandUSD 190 mn1.0%USD 413 mn8.1%
15MexicoUSD 159 mn0.8%USD 432 mn10.5%
16NetherlandsUSD 159 mn0.8%USD 348 mn8.2%
17TurkeyUSD 159 mn0.8%USD 432 mn10.5%
18IrelandUSD 159 mn0.8%USD 348 mn8.2%
19RussiaUSD 128 mn0.7%USD 279 mn8.1%
20BelgiumUSD 128 mn0.7%USD 279 mn8.1%
21TaiwanUSD 128 mn0.7%USD 279 mn8.1%
22Saudi ArabiaUSD 94 mn0.5%USD 260 mn10.7%
23PolandUSD 94 mn0.5%USD 209 mn8.3%
24SwedenUSD 94 mn0.5%USD 209 mn8.3%
25DenmarkUSD 94 mn0.5%USD 209 mn8.3%
Rest of worldUSD 791 mn4.0%USD 1.8 bn8.8%
Exhibit 5United States and China account for 55% of the USD 26.8 bn the market is forecast to add by 2036Forecast revenue added between 2026 and 2036 by country, in USD
Injectable Drug Delivery market, where the growth to 2036 comes fromRevenue added between 2026 and 2036. Market value 2026: USD 19.6 bn. United States: +USD 11.7 bn; China: +USD 3.2 bn; Germany: +USD 1.7 bn; India: +USD 1.2 bn; Japan: +USD 1.1 bn; 20 other countries: +USD 6.9 bn; Rest of world: +USD 1.0 bn. Market value 2036: USD 46.4 bn.Market value 202619.6 bnUnited States+11.7 bnChina+3.2 bnGermany+1.7 bnIndia+1.2 bnJapan+1.1 bn20 other countries+6.9 bnRest of world+1.0 bnMarket value 203646.4 bn

Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.

Competitive landscape

Group 1: Global leaders

  • BD
  • Gerresheimer
  • SCHOTT Pharma
  • Stevanato Group
  • West Pharmaceutical Services
  • Terumo
  • Phillips-Medisize
  • Nemera

Group 2: Regional and specialist players

  • Ypsomed
  • SHL Medical
  • Owen Mumford
  • Nipro
  • Haselmeier
  • medmix
  • Biocorp
  • Aptar Pharma
  • Shandong Weigao Group

Group 3: Emerging and niche players

  • Credence MedSystems
  • PharmaJet
  • Bespak
  • Enable Injections
  • Subcuject
  • Injex Pharma
  • Windgap Medical

Research methodology

Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the injectable drug delivery market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.

The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 9.0% is calculated from the resulting values.

The market is divided by device, by therapy, by end user, by container material, by administration route. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.

Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.

Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.

Read the full research methodology

Frequently asked questions

How big is the injectable drug delivery market?

The global injectable drug delivery market is estimated at USD 18.0 bn in 2025 and USD 19.6 bn in 2026.

How fast will the injectable drug delivery market grow?

It is forecast to reach USD 46.4 bn by 2036, a compound annual growth rate of 9.0% from 2026, an increase of USD 26.8 bn.

Which country is the largest market for injectable drug delivery?

United States is the largest market by revenue at USD 8.2 bn in 2026, 42.0% of the global total. The three largest countries together hold 58.0%.

Which country is growing fastest?

Among the ten largest markets, China is growing fastest at 11.7% a year from 2026 to 2036.

Which injectable drug delivery segment is largest?

In the by device split, Prefilled syringes is the largest segment with 38.0% of 2026 revenue.

Who are the leading injectable drug delivery companies?

Global leaders include BD, Gerresheimer, SCHOTT Pharma, Stevanato Group.

Need the full report?

Request a sample to see the structure, tables and country detail.

Request a free sample

Related markets in Healthcare

← Inhalation Drug Delivery Insulin Delivery →

All Healthcare markets →

Request a sample